STOCK TITAN

OKYO Pharma Limited - OKYO STOCK NEWS

Welcome to our dedicated news page for OKYO Pharma (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OKYO Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OKYO Pharma's position in the market.

Rhea-AI Summary
OKYO Pharma Limited has announced a registered direct offering of 1,092,600 ordinary shares at an offering price of $1.50 per share, resulting in gross cash proceeds of $1.64M. Additionally, the company will extinguish $4.20M of payables by issuing 2,766,667 ordinary shares at the same offering price. This reduction in payables is seen as a significant endorsement of the company's strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
none
-
Rhea-AI Summary
OKYO Pharma plans to initiate a clinical trial for OK-101 to treat Neuropathic Corneal Pain (NCP). The trial will be led by Dr. Pedram Hamrah and enrollment is planned for Q1 2024. OK-101 is also currently in a Phase 2 clinical trial for dry eye disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
none
-
Rhea-AI Summary
OKYO Pharma announces positive safety profile for OK-101 in Phase 2 trial for DED treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
Rhea-AI Summary
OKYO Pharma closes direct offering of 2.7M shares at $1.50 per share, raising $4.0M for clinical development and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.43%
Tags
-
Rhea-AI Summary
OKYO Pharma announces pricing of registered direct offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.61%
Tags
-
Rhea-AI Summary
OKYO Pharma withdraws proposed public offering of ordinary shares and terminates underwriter due to changing market conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.61%
Tags
Rhea-AI Summary
OKYO Pharma announces intention to sell ordinary shares in underwritten public offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.61%
Tags
-
Rhea-AI Summary
OKYO Pharma completes full enrollment of patients in Phase 2 trial of OK-101 to treat dry eye disease (DED)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
-
Rhea-AI Summary
OKYO Pharma enrolls 90% of patients in Phase 2 trial for DED drug OK-101, expects full enrollment by September and top-line data by end of 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.76%
Tags
Rhea-AI Summary
OKYO Pharma regains compliance with Nasdaq minimum market value requirement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.61%
Tags
none
OKYO Pharma Limited

Nasdaq:OKYO

OKYO Rankings

OKYO Stock Data

46.03M
13.64M
25.72%
2.53%
0.55%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Guernsey
Admiral Park